title: Cabergoline versus levodopa monotherapy.
authors.forename: Keith
authors.initials: K
authors.lastname: Wheatley
authors.forename: Carl E
authors.initials: CE
authors.lastname: Clarke
authors.forename: Natalie
authors.initials: N
authors.lastname: Ives
authors.forename: Richard
authors.initials: R
authors.lastname: Gray
mesh_terms: D000978:Antiparkinson Agents / Q000191:economics / Q000627:therapeutic use*; D000077465:Cabergoline; D003362:Cost-Benefit Analysis; D004873:Ergolines / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000191:economics / Q000627:therapeutic use*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics
chemical_list: D000978:Antiparkinson Agents; D004873:Ergolines; D007980:Levodopa; D000077465:Cabergoline